Redeye initiates coverage of Scandion Oncology, a Danish pharma company developing drugs to reverse chemotherapy resistance – the reason for almost all cancer patient deaths. Urgent medical need (no approved treatments), a large addressable market and promising phase I/II data put lead candidate SCO-101 on track for blockbuster status and translate into significant upside potential, while platform label expansion lays out a clear future growth path.